FDL 176

Drug Profile

FDL 176

Alternative Names: FDL176

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Flatley Discovery Lab
  • Class
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 27 Jun 2017 Phase-I clinical trials in Cystic fibrosis in Australia (PO) (NCT03173573)
  • 09 Jun 2017 Flatley Discovery Lab plans a phase I trial for Cystic fibrosis (NCT03173573)
  • 01 Jun 2016 Preclinical trials in Cystic fibrosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top